Toggle Main Menu Toggle Search

ePrints

The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial

Lookup NU author(s): Dr Kieren Hollingsworth, Professor Ashley Adamson, Professor Falko Sniehotta, Professor John Mathers, Dr Carl Peters, Alison Barnes, Dr Angela Rodrigues, Dr Lucia Rehackova, Dr Sviatlana Zhyzhneuskaya, Professor Roy Taylor

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

Background: Despite improving evidence-based practice following clinical guidelines to optimise drug therapy, Type 2 diabetes (T2DM) still exerts a devastating toll from vascular complications and premature death. Biochemical remission of T2DM has been demonstrated with weight loss around 15kg following bariatric surgery and in several small studies of non-surgical energy-restriction treatments. The non-surgical Counterweight-Plus programme, running in Primary Care where obesity and T2DM are routinely managed, produces >15 kg weight loss in 33 % of all enrolled patients. The Diabetes UK-funded Counterpoint study suggested that this should be sufficient to reverse T2DM by removing ectopic fat in liver and pancreas, restoring first-phase insulin secretion.The Diabetes Remission Clinical Trial (DiRECT) was designed to determine whether a structured, intensive, weight management programme, delivered in a routine Primary Care setting, is a viable treatment for achieving durable normoglycaemia. Other aims are to understand the mechanistic basis of remission and to identify psychological predictors of response.Methods/Design: Cluster-randomised design with GP practice as the unit of randomisation: 280 participants from around 30 practices in Scotland and England will be allocated either to continue usual guideline-based care or to add the Counterweight-Plus weight management programme, which includes primary care nurse or dietitian delivery of 12-20 weeks low calorie diet replacement, food reintroduction, and long-term weight loss maintenance. Main inclusion criteria: men and women aged 20-65 years, all ethnicities, T2DM 0-6 years duration, BMI 27-45 kg/m(2). Tyneside participants will undergo Magnetic Resonance (MR) studies of pancreatic and hepatic fat, and metabolic studies to determine mechanisms underlying T2DM remission. Co-primary endpoints: weight reduction >= 15 kg and HbA1c <48 mmol/mol at one year. Further follow-up at 2 years.Discussion: This study will establish whether a structured weight management programme, delivered in Primary Care by practice nurses or dietitians, is a viable treatment to achieve T2DM remission. Results, available from 2018 onwards, will inform future service strategy.


Publication metadata

Author(s): Leslie WS, Ford I, Sattar N, Hollingsworth KG, Adamson A, Sniehotta FF, McCombie L, Brosnahan N, Ross H, Mathers JC, Peters C, Thom G, Barnes A, Kean S, McIlvenna Y, Rodrigues A, Rehackova L, Zhyzhneuskaya S, Taylor R, Lean MEJ

Publication type: Article

Publication status: Published

Journal: BMC Family Practice

Year: 2016

Volume: 17

Online publication date: 16/01/2016

Acceptance date: 21/01/2016

ISSN (electronic): 1471-2296

Publisher: BioMed Central Ltd.

URL: http://dx.doi.org/10.1186/s12875-016-0406-2

DOI: 10.1186/s12875-016-0406-2


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share